Alzheimer's Drug Approved by Health Canada
Lecanemab aims to slow early stages of the disease by targeting plaques in the brain.
When someone is diagnosed with dementia, a common fear is losing the ability to stay independent. The conditional approval of a medication for early Alzheimer's in Canada is being called a positive development.
Health Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.
- Lecanemab is a lab-made antibody given by intravenous infusion.
- It targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country.
Author's summary: Lecanemab approved to slow early Alzheimer's.
More News
- Performa brings digital doubles, kids reciting animal noises and more to New York
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- Stranger Things 5 trailer shows way more than we were ready for
- Dean Lewis Shares Statement Following Misconduct Allegations
- NewJeans to Appeal Label Contract Court Decision
- Coup scare: DSS and selective use of state power
- How MorningStar and Anthem Are Revamping Scheduling and Staffing Efficiency
- Billie Eilish Calls on Billionaires to Do More for People in Need
- City unveils plan for new stage, remodel of Coleman Hawkins Park next spring